# OnCo record paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019" ;
  schema:name "Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)"@en ;
  schema:alternateName "PHOENIX trial"@en, "Younes 2019"@en, "Ibrutinib with R-CHOP in non-germinal centre diffuse large B-cell lymphoma"@en ;
  schema:description "Adding a targeted tablet to standard first-line chemotherapy failed overall, helped people under 60 substantially, and harmed people over 60 by making them unable to finish the chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.18.02403>, <https://pubmed.ncbi.nlm.nih.gov/30901302/>, <https://europepmc.org/article/MED/30901302> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.18.02403> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Younes A, Sehn LH, Johnson P, et al." ;
  onco:related <https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/>, <https://onco.cc/key-papers/paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004/>, <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/cell-of-origin/> ;
  onco:trials <https://onco.cc/trials/phoenix/>, <https://onco.cc/trials/arched/> ;
  onco:people <https://onco.cc/people/laurie-sehn/>, <https://onco.cc/people/peter-johnson/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/jco/> .